Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685558 | 0.93 | TTR (0.37) | CYP3A4TSHRMAPK1TTRALDH1A1 | |
| SCHEMBL1369255 | 0.89 | TTR (0.35) | CYP3A4TSHRMAPK1TTR | |
| SCHEMBL31291547 | 0.86 | TTR (0.33) | TTR | |
| SCHEMBL12803312 | 0.86 | TTR (0.33) | TTR | |
| SCHEMBL30708616 | 0.85 | CYP3A4 (0.37) | CYP3A4TSHRMAPK1TTRALDH1A1 | |
| SCHEMBL13584339 | 0.85 | CYP3A4 (0.37) | CYP3A4TSHRMAPK1TTRALDH1A1 | |
| SCHEMBL14859846 | 0.80 | LMNA (0.33) | TTR | |
| SCHEMBL15593248 | 0.80 | NQO2 (0.31) | CYP3A4TSHRMAPK1TTR | |
| SCHEMBL18892550 | 0.76 | TTR (0.32) | TTR | |
| SCHEMBL19526470 | 0.76 | LDHA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490658-B | Preparation method of 4,4' -oxydiphthalic anhydride | 天津众泰材料科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-115490658-A | Preparation method of 4,4' -oxydiphthalic anhydride | 天津众泰材料科技有限公司 | 2022-12-20 | — | — | CN | claimed |
| EP-4400561-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024052363-A1 | POLYMERIZABLE LIQUID CRYSTAL MATERIAL AND POLYMERIZED LIQUID CRYSTAL FILM | MERCK PATENT GMBH (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-4306614-A1 | LIQUID-CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023237572-A1 | POLYMERISABLE LIQUID CRYSTAL MEDIUM AND POLYMERISED LIQUID CRYSTAL FILM | MERCK PATENT GMBH (DE) | 2023-12-14 | — | — | WO | disclosed |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| CN-115490658-B | Preparation method of 4,4' -oxydiphthalic anhydride | 天津众泰材料科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023198671-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| US-11793063-B2 | Condensed-cyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6365776-B1 | FROM ORGANOHALOGEN COMPOUND AND AMINE USING PALLADIUM COMPOUND CATALYST AND PROMOTER | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-04-02 | — | — | US | disclosed |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TAKASAGO INTERNATIONAL CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0802173-B1 | Process for producing heterocylic aromatic amine or arylamine | TOSOH CORP (JP) | 2001-12-19 | — | — | EP | disclosed |
| EP-1061112-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-5929281-A | REACTING A HETROCYCLIC AROMATIC HALIDE WITH AN AMINE COMPOUND IN PRESENCE OF A BASE USING A TRI-TERT-BUTYLPHOSPHINE AND PALLADIUM COMPOUND CATALYST TO FORM HETEROCYCLIC AROMATIC AMINE COMPOUNDS | TOSOH CORPORATION (JP) | 1999-07-27 | — | — | US | disclosed |
| EP-0802173-A1 | Process for producing heterocylic aromatic amine or arylamine | Tosoh Corporation (JP) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793063-B2 | Condensed-cyclic compound and organic light emitting device including the same | CRY1, CRY2, CCNE2 | CYP3A4 1257/4885TSHR 4294/4885MAPK1 2070/4885 |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TYR, DDC, PNMT | CYP3A4 301/4885TSHR 2516/4885MAPK1 1677/4885 |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | CYP3A4 1390/4885TSHR 2225/4885MAPK1 1764/4885 |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | L1CAM, CHRM1, FOXM1 | CYP3A4 256/4885TSHR 2605/4885MAPK1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.